Dmitrij Hristodorov PhD
General Partner
Developing a regenerative medicine for MS that can improve quality of life for patients
Progentos is developing a regenerative medicine for MS that can improve quality of life for patients. The company's scientists have identified and validated a novel target that generates clear and compelling remyelination in pre-clinical studies.
Progentos' compounds are designed to activate progenitor cells in the brain to form new oligodendrocytes and remyelinate neurons. Remyelination could prevent further decline or, potentially, even restore function.
Industry
Biotech
Status
Current
Location
US
We benefited greatly from Forbion’s leadship and guidance as we brought an A-round syndicate together for Progentos. Forbion’s scientific depth and track record of success accelerated the fundraising process and led to an oversubscribed round of top tier investors.Chris Loose
CEO
$65m
funding emerged with
Forbion team
Marc-Olivier Turgeon PhD
Senior Associate